Oncotelic Therapeutics Secures Convertible Debt Financing Agreement

Oncotelic Therapeutics ( (OTLC) ) has provided an announcement.

On January 23, 2026, Oncotelic Therapeutics secured $398,333 in convertible debt from Mast Hill Fund, issuing a one-year, 10% secured note convertible at $0.07 per share, together with 1,422,613 warrants at $0.15, and restricted the use of proceeds to working capital. The agreement, backed by most company assets and paired with registration rights for the conversion shares and warrants, underscores a leverage-heavy financing that could dilute equity while bolstering near-term liquidity for ongoing oncology programs.

The most recent analyst rating on (OTLC) stock is a Hold with a $0.07 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.

Spark’s Take on OTLC Stock

According to Spark, TipRanks’ AI Analyst, OTLC is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue characteristics, ongoing losses, and continued cash burn) combined with elevated balance-sheet leverage. Technicals also reflect recent weakness (negative MACD; price below key short/intermediate moving averages). Corporate actions around financing and debt milestones provide some support, but they are offset by ongoing dependence on capital markets and dilution risk; valuation signals are limited due to negative earnings.

To see Spark’s full report on OTLC stock, click here.

More about Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical-stage biotechnology company focused on oncology assets such as OT-101, CA4P, Oxi4503, AI-driven therapies, and nanoparticle platforms, targeting unmet cancer indications.

Average Trading Volume: 176,699

Technical Sentiment Signal: Buy

Current Market Cap: $35.01M

For an in-depth examination of OTLC stock, go to TipRanks’ Overview page.